Explore

Trendline Trendline
Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes Treatment

Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes Treatment

Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes Treatment
Rapid Read Rapid Read
Diabetes Association Faces Backlash After Expelling Members Over NIH Protest

Diabetes Association Faces Backlash After Expelling Members Over NIH Protest

The American Diabetes Association (ADA) is under fire after expelling five members from its annual meeting for protesting federal cuts to biomedical research. The expelled members were distributing an editorial critical of the Trump administration's policies and the National Institutes of Health (NIH) director, Jay Bhattacharya. The ADA's actions have sparked outrage among its members, with calls for an apology or leadership change. The incident has raised concerns about the organization's commitment to scientific integrity and its handling of dissenting views.
Rapid Read Rapid Read
Tidepool Unveils New Diabetes Management Data and Women's Health Initiative at ADA 2026

Tidepool Unveils New Diabetes Management Data and Women's Health Initiative at ADA 2026

Tidepool, a nonprofit organization focused on diabetes technology, presented new clinical data and research initiatives at the American Diabetes Association's 86th Scientific Sessions. The presentation highlighted the effectiveness of a 24-week Diabetes Care Management Program (DCMP) in resource-limited settings, which utilized continuous glucose monitoring (CGM) data to improve patient outcomes. The program achieved a 1.59% reduction in HbA1c levels and a 13.4% increase in Time in Range for patients with uncontrolled type 2 diabetes. Additionally, Tidepool announced a landmark initiative aimed at addressing gender equity in diabetes research, focusing on women's health. This initiative seeks to create a large, anonymized dataset of biometric and diabetes device data to better understand and address the unique health challenges faced by women with diabetes.
Rapid Read Rapid Read
Dexcom's CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients Not Using Insulin

Dexcom's CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients Not Using Insulin

Dexcom, Inc. has announced the results of its CONNECT randomized controlled trial, which demonstrates the significant benefits of using the Dexcom G7 continuous glucose monitoring (CGM) system for individuals with Type 2 diabetes who are not using insulin. The study, presented at the 2026 Scientific Sessions of the American Diabetes Association, showed that participants using the Dexcom G7 experienced a clinically and statistically significant reduction in HbA1c levels and improved glucose control compared to those using traditional self-monitoring methods. The trial involved 283 participants across 22 primary care practices in the United States, with 265 completing the 26-week study. Key outcomes included an average 1.6% reduction in HbA1c levels for those using the Dexcom G7, with significant improvements in time spent within the target glucose range.
Rapid Read Rapid Read
Insulin Inhaler Offers New Hope for Type 1 Diabetes Management

Insulin Inhaler Offers New Hope for Type 1 Diabetes Management

A new medical breakthrough has emerged, offering a potential alternative to traditional insulin injections for individuals with Type 1 diabetes. This development involves the use of an insulin inhaler, which could provide a less invasive method for managing the condition. The innovation is particularly significant for millions of Americans who rely on daily insulin injections to regulate their blood sugar levels. The inhaler could simplify the administration of insulin, improving the quality of life for those affected by the disease.
Trendline Trendline
Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes

Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes

Century Therapeutics Unveils Promising Preclinical Data for CNTY-813 in Type 1 Diabetes
Rapid Read Rapid Read
Dexcom CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients

Dexcom CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients

DexCom, Inc. has announced the results of the CONNECT randomized controlled trial, which demonstrates significant benefits of using the Dexcom G7 continuous glucose monitoring (CGM) system for people with Type 2 diabetes not using insulin. The study, presented at the 2026 Scientific Sessions of the American Diabetes Association, showed that the use of Dexcom G7 led to a clinically and statistically significant reduction in HbA1c levels and improved glucose control compared to routine care. The trial involved 283 participants across the United States, with results indicating a 1.6% average reduction in HbA1c for those using the Dexcom G7. The study highlights the potential of CGM systems to become a new standard of care for managing Type 2 diabetes.
Rapid Read Rapid Read
Corcept Therapeutics Presents Data on Cortisol Modulation for Type 2 Diabetes at ADA

Corcept Therapeutics Presents Data on Cortisol Modulation for Type 2 Diabetes at ADA

Corcept Therapeutics Incorporated has presented new data from its CATALYST and MOMENTUM trials at the American Diabetes Association's 86th Scientific Sessions. The data highlights the role of hypercortisolism in difficult-to-control type 2 diabetes and resistant hypertension, and the potential benefits of cortisol modulation treatment. The CATALYST trial screened over 1,000 patients with difficult-to-control type 2 diabetes, finding that 24% had hypercortisolism. Patients treated with Korlym showed significant improvements in metabolic parameters, including reductions in hemoglobin A1c, body weight, and waist circumference. The MOMENTUM trial also found a high prevalence of hypercortisolism in patients with resistant hypertension.
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment
Trendline Trendline
Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702
Rapid Read Rapid Read
insitro's AI-Discovered MASH Candidate Shows Promise in Reducing Liver Fibrosis

insitro's AI-Discovered MASH Candidate Shows Promise in Reducing Liver Fibrosis

Insitro, a company specializing in AI-driven drug discovery, presented new preclinical data at the American Diabetes Association's 86th Scientific Sessions. The data highlights the potential of their lead therapeutic candidate, CTRO-1013, in reducing fibrosis progression in metabolic dysfunction-associated steatohepatitis (MASH). The study demonstrated that liver-targeted silencing of IRS1, a genetic target identified by insitro's AI platform, lowered biomarkers associated with fibrosis and liver injury in preclinical models. These findings suggest that IRS1 inhibition could offer a new therapeutic approach for MASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis.
Trendline Trendline
Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO

Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO

Kailera Therapeutics Advances Obesity Treatment with Record-Breaking IPO